ATE223704T1 - METHOD FOR PRODUCING WAX MATRICES - Google Patents

METHOD FOR PRODUCING WAX MATRICES

Info

Publication number
ATE223704T1
ATE223704T1 AT93922628T AT93922628T ATE223704T1 AT E223704 T1 ATE223704 T1 AT E223704T1 AT 93922628 T AT93922628 T AT 93922628T AT 93922628 T AT93922628 T AT 93922628T AT E223704 T1 ATE223704 T1 AT E223704T1
Authority
AT
Austria
Prior art keywords
wax matrices
producing wax
matrices
producing
achieve
Prior art date
Application number
AT93922628T
Other languages
German (de)
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ATE223704T1 publication Critical patent/ATE223704T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
    • B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
    • B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders

Abstract

A method capable of manufacturing wax matrices efficiently in large quantities at once characterized in that a multiscrew extruder is used to achieve the object.
AT93922628T 1992-10-16 1993-10-14 METHOD FOR PRODUCING WAX MATRICES ATE223704T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30498692 1992-10-16
PCT/JP1993/001472 WO1994008568A1 (en) 1992-10-16 1993-10-14 Method of manufacturing wax matrices

Publications (1)

Publication Number Publication Date
ATE223704T1 true ATE223704T1 (en) 2002-09-15

Family

ID=17939698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93922628T ATE223704T1 (en) 1992-10-16 1993-10-14 METHOD FOR PRODUCING WAX MATRICES

Country Status (10)

Country Link
US (1) US5700410A (en)
EP (1) EP0665010B1 (en)
JP (1) JP2616252B2 (en)
KR (1) KR100291362B1 (en)
AT (1) ATE223704T1 (en)
AU (1) AU5160893A (en)
CA (1) CA2147283C (en)
DE (1) DE69332291T2 (en)
ES (1) ES2180548T3 (en)
WO (1) WO1994008568A1 (en)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5688510A (en) * 1993-11-18 1997-11-18 Nippon Shinyaku Co. Ltd. Process for producing stable medicinal composition, and pharmaceutical preparation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
FR2729077A1 (en) * 1995-01-05 1996-07-12 Oreal COSMETIC COMPOSITION IN THE FORM OF A SOFT PASTE AND PROCESS FOR PREPARING THE SAME
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
ES2287971T3 (en) * 1997-08-11 2007-12-16 Pfizer Products Inc. SOLID PHARMACEUTICAL DISPERSIONS WITH INCREASED BIODISPONIBILITY.
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
ITMI991316A1 (en) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
CN102716101A (en) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
SE0003125D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20040010035A1 (en) * 2002-07-15 2004-01-15 Ciociola Arthur A. Gastrointestinal compositions
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
WO2004006902A1 (en) * 2002-07-10 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
KR20040016202A (en) * 2002-08-16 2004-02-21 주식회사 제이알팜 The composition and method for masking bitter taste of hydrocortisone oral preparations
EP1617838A4 (en) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Composition for oral administration containing alkylene dioxybenzene derivative
US7364755B2 (en) * 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
RU2007143556A (en) * 2005-04-25 2009-06-10 ТЕВА ФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. (US) PROLONGED RELEASE COMPOSITIONS
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1933852B1 (en) * 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
JP5334588B2 (en) 2005-11-28 2013-11-06 マリナス ファーマシューティカルズ Ganaxolone preparation, method for producing the same, and use thereof
KR20080080655A (en) 2005-12-22 2008-09-04 오츠카 세이야쿠 가부시키가이샤 Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
GB0600913D0 (en) * 2006-01-17 2006-02-22 Syngenta Ltd Improvements in or relating to organic compounds
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
US20070243237A1 (en) * 2006-04-14 2007-10-18 Mazen Khaled Antimicrobial thin film coating and method of forming the same
ATE510538T1 (en) 2006-08-11 2011-06-15 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR NERVE PROTECTION
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP2200607A4 (en) 2007-09-10 2012-02-22 Calcimedica Inc Compounds that modulate intracellular calcium
BRPI0917719A2 (en) 2008-08-27 2019-11-19 Calcimedica Inc intracellular calcium modulating compounds
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011090724A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with lipid-based low-density excipient
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2563776B1 (en) 2010-04-27 2016-06-08 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX337711B (en) 2010-08-27 2016-03-15 Calcimedica Inc Compounds that modulate intracellular calcium.
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9492423B2 (en) 2011-09-13 2016-11-15 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US9364549B2 (en) * 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3698782A1 (en) 2012-01-06 2020-08-26 Lundbeck La Jolla Research Center, Inc. Carbamate compounds for use in therapy
MY187999A (en) 2012-06-04 2021-11-08 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
JP2015528001A (en) 2012-07-11 2015-09-24 ティッシュテック，インク． Composition comprising HC-HA / PTX3 complex and method of use thereof
CA2885828C (en) 2012-09-28 2021-04-27 University Of Washington Through Its Center For Commercialization Ureido-thiophenyl derivatives, compositions thereof and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
BR112016012728A2 (en) 2013-12-05 2020-08-11 Pharmacyclics Llc bruton tyrosine kinase inhibitor compounds, pharmaceutical composition comprising them and use thereof
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (en) 2014-06-03 2016-02-01 組織科技股份有限公司 Compositions and methods
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10399994B2 (en) 2015-02-06 2019-09-03 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EA039121B1 (en) 2015-02-27 2021-12-07 Куртана Фармасьютикалс, Инк. INHIBITION OF Olig2 ACTIVITY
TW202315634A (en) 2015-03-03 2023-04-16 美商製藥公司 Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor
MA41828A (en) 2015-03-27 2018-01-30 Pharmacyclics Llc CO-CRYSTALS OF A TYROSINE KINASE INHIBITOR FROM BRUTON
MA41827A (en) 2015-03-27 2018-01-30 Pharmacyclics Llc SOLVATED FORMS OF A BRUTON TYROSINE KINASE INHIBITOR
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
CN107847526A (en) 2015-05-20 2018-03-27 组织技术公司 For preventing the propagation of epithelial cell and the composition and method of the conversion of epithelium mesenchyma
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
ES2952064T3 (en) 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Cytokine-induced inhibition of SH2 protein in NK cells
EP3405178A1 (en) 2016-01-19 2018-11-28 Janssen Pharmaceutica NV Formulations/compositions comprising a btk inhibitor
EA201891440A1 (en) 2016-01-19 2018-12-28 Янссен Фармацевтика Нв COMPOSITIONS / COMPOSITIONS CONTAINING BTK INHIBITOR
TW201733600A (en) 2016-01-29 2017-10-01 帝聖工業公司 Fetal support tissue products and methods of use
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
JP7049683B2 (en) 2016-04-04 2022-04-07 シノピア バイオサイエンシーズ，インク． Treatment of extrapyramidal syndrome with trapidil
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
DK3484862T3 (en) 2016-07-18 2021-11-08 Arthrosi Therapeutics Inc Compounds, compositions and methods for treating or preventing a symptom associated with arthritis or hyperuricemia
KR102468670B1 (en) 2016-08-26 2022-11-17 커타나 파마슈티칼스, 인크. Inhibition of OLIG2 activity
ES2900016T3 (en) 2016-11-16 2022-03-15 H Lundbeck As A crystalline form of a MAGL inhibitor
JP2020500176A (en) 2016-11-16 2020-01-09 ルンドベック ラ ホーヤ リサーチ センター，インク． Pharmaceutical preparations
AU2018325267B2 (en) 2017-09-01 2023-03-30 University Of Washington Crystalline forms of compounds for preventing or treating sensory hair cell death
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
TW202019887A (en) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 Pegylated prodrugs of phenolic trpv1 agonists
BR112021011578A2 (en) 2018-12-31 2021-08-31 Biomea Fusion, Llc IRREVERSIBLE GIRL-MLL INTERACTION INHIBITORS
EP3937938A1 (en) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandil derivatives
JP2023523219A (en) 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット Synthesis of monoacylglycerol lipase inhibitors
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20240010649A1 (en) 2022-07-06 2024-01-11 Oppilan Pharma Limited Crystalline forms of an s1p receptor modulator

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2245640A (en) * 1936-04-10 1941-06-17 Tide Water Associated Oil Comp Method of molding paraffin wax
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3487138A (en) * 1966-11-23 1969-12-30 Merck & Co Inc Process for preparing a delayed release medicinal tablet
DE2426811A1 (en) * 1974-06-04 1976-01-08 Klinge Co Chem Pharm Fab PROCESS FOR THE MANUFACTURING OF RETARD TABLETS
DE2426812A1 (en) * 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab PROCESS FOR THE MANUFACTURING OF GRANULES
DE2439538C3 (en) * 1974-08-17 1980-07-17 Ludwig Heumann & Co Gmbh, 8500 Nuernberg Process for the manufacture of orally administered drugs with delayed release of action
FR2581541B1 (en) * 1985-05-09 1988-05-20 Rhone Poulenc Sante NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF AN ACTIVE INGREDIENT AND THEIR PREPARATION METHOD
ATE87469T1 (en) * 1985-12-27 1993-04-15 Sumitomo Pharma PROCESS FOR THE MANUFACTURE OF A DELAYED RELEASE FORMULATION.
DE3812567A1 (en) * 1988-04-15 1989-10-26 Basf Ag METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix agent
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
US5151026A (en) * 1990-10-31 1992-09-29 Werner & Pfleiderer Corp. Apparatus for removing liquids from solids
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
DE4127665A1 (en) * 1991-08-22 1993-02-25 Beiersdorf Ag GALENIC MATRIX
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments

Also Published As

Publication number Publication date
AU5160893A (en) 1994-05-09
WO1994008568A1 (en) 1994-04-28
JP2616252B2 (en) 1997-06-04
EP0665010B1 (en) 2002-09-11
CA2147283C (en) 2007-01-16
DE69332291T2 (en) 2003-07-31
EP0665010A1 (en) 1995-08-02
KR100291362B1 (en) 2001-09-17
EP0665010A4 (en) 1996-02-28
US5700410A (en) 1997-12-23
CA2147283A1 (en) 1994-04-28
KR950703332A (en) 1995-09-20
DE69332291D1 (en) 2002-10-17
ES2180548T3 (en) 2003-02-16

Similar Documents

Publication Publication Date Title
DE69332291D1 (en) METHOD FOR PRODUCING WAX MATRICES
DE69103062D1 (en) Process for the production of unsaturated aldehydes and unsaturated acids.
DE69221283D1 (en) Process for the production of polysilanes
DE69222979D1 (en) Process for the production of microlenses
DE68924619T2 (en) Stereolithographic process for the production of prostheses.
DE69214572T2 (en) Process for the production of alcohols
DE69219393T2 (en) Process for the production of microcapsules
DE3751551D1 (en) Lithographic process using lasers to manufacture electronic elements and the like.
DE69309808T2 (en) Process for the production of unsaturated alcohols
DE59304179D1 (en) Thermoplastic molding compositions for the production of inorganic sintered molded parts and process for producing inorganic sintered molded parts
DE69321358D1 (en) METHOD FOR PRODUCING SPUNNED THREADS
DE3854716T2 (en) Process for producing thermoplastic resin composition.
DE59205125D1 (en) METHOD FOR PRODUCING UNSATURATED FATTY ALCOHOLS
DE69208587T2 (en) Process for the production of thermoplastic resins
ATA163789A (en) METHOD FOR PRODUCING CERAMIC MOLDED PARTS
DE69314835T2 (en) Process for the production of fuel from waste
DE69318989D1 (en) METHOD FOR PRODUCING THERMOPLASTIC PELLETS WITH LUBRICANTS
DE69327203T2 (en) Process for the production of metallocenes
DE3874260D1 (en) METHOD FOR PRODUCING ESTERS OF UNSATURATED ALCOHOLS.
DE69316702T2 (en) Process for the production of polymer particles with an irregular shape
DE69106370T2 (en) METHOD FOR PRODUCING TOOLS AND MATRICES.
DE59207888D1 (en) Process for the production of anti-reflective surfaces
AT366693B (en) METHOD FOR PRODUCING PENICILLANIC ACID 1,1-DIOXIDE AND ITS ESTERS
DE69310725D1 (en) METHOD FOR PRODUCING HOLLOW MOLDED BODIES
DE3751769D1 (en) Photosensitive plastic composition and method for producing fine structures with this composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties